Aldeyra Therapeutics (NASDAQ:ALDX) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of Aldeyra Therapeutics (NASDAQ:ALDX) from a sell rating to a hold rating in a research report report published on Saturday morning.

Other research analysts also recently issued research reports about the stock. BTIG Research restated a “buy” rating on shares of Aldeyra Therapeutics in a report on Tuesday, March 17th. HC Wainwright restated a “neutral” rating and set a $2.00 price objective (down from $10.00) on shares of Aldeyra Therapeutics in a report on Wednesday, March 18th. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $5.50.

Aldeyra Therapeutics Price Performance

Aldeyra Therapeutics stock opened at $1.80 on Friday. The firm has a market cap of $108.33 million, a price-to-earnings ratio of -3.16 and a beta of 1.34. Aldeyra Therapeutics has a fifty-two week low of $1.07 and a fifty-two week high of $6.18. The firm has a fifty day moving average price of $3.48 and a two-hundred day moving average price of $4.51.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its earnings results on Friday, February 27th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.03. As a group, sell-side analysts expect that Aldeyra Therapeutics will post -0.92 earnings per share for the current year.

Insider Activity

In related news, Director Richard Douglas acquired 70,000 shares of the company’s stock in a transaction dated Thursday, March 19th. The shares were bought at an average price of $1.40 per share, for a total transaction of $98,000.00. Following the acquisition, the director owned 195,000 shares in the company, valued at $273,000. This trade represents a 56.00% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 9.60% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ALDX. Krilogy Financial LLC bought a new stake in Aldeyra Therapeutics in the first quarter valued at about $26,000. Invesco Ltd. increased its stake in Aldeyra Therapeutics by 22.0% in the fourth quarter. Invesco Ltd. now owns 163,087 shares of the biotechnology company’s stock valued at $845,000 after acquiring an additional 29,382 shares during the period. XTX Topco Ltd increased its stake in Aldeyra Therapeutics by 22.5% in the fourth quarter. XTX Topco Ltd now owns 42,227 shares of the biotechnology company’s stock valued at $219,000 after acquiring an additional 7,761 shares during the period. Caption Management LLC bought a new stake in Aldeyra Therapeutics in the fourth quarter valued at about $181,000. Finally, 683 Capital Management LLC increased its stake in Aldeyra Therapeutics by 86.6% in the fourth quarter. 683 Capital Management LLC now owns 1,530,000 shares of the biotechnology company’s stock valued at $7,925,000 after acquiring an additional 710,000 shares during the period. Institutional investors own 59.71% of the company’s stock.

Trending Headlines about Aldeyra Therapeutics

Here are the key news stories impacting Aldeyra Therapeutics this week:

• Negative Sentiment: Rosen Law Firm reminded Aldeyra investors of the May 29, 2026 lead‑plaintiff deadline in the securities class action it first filed; invites affected purchasers to secure counsel. ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ALDX
• Negative Sentiment: Kirby McInerney LLP issued a shareholder alert urging Aldeyra purchasers to contact the firm by May 29, 2026 to discuss claims in the securities fraud class action. ALDX SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of Aldeyra Therapeutics Investors – Contact Kirby McInerney LLP by May 29, 2026
• Negative Sentiment: The Schall Law Firm says investors may pursue leadership in a suit alleging violations of Sections 10(b) and 20(a) and Rule 10b‑5 for purchases during the stated class period. ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc Securities Fraud Lawsuit with the Schall Law Firm
• Negative Sentiment: The Gross Law Firm issued a shareholder alert inviting investors with losses to join the class action covering the same class period. ALDX Shareholder Alert: Aldeyra Therapeutics, Inc Securities Class Action Lawsuit Investors With Losses May Join — The Gross Law Firm
• Negative Sentiment: Faruqi & Faruqi, LLP reminds investors of the May 29 deadline and is investigating potential claims against Aldeyra for purchases within the class period. ALDX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026
• Negative Sentiment: Pomerantz LLP issued an investor alert about the class action and upcoming deadlines for shareholders with losses. INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines – ALDX
• Negative Sentiment: SueWallSt’s alert alleges executives “allegedly disregarded FDA requirements” and reiterates the May 29 deadline for lead‑plaintiff motions — language that may heighten investor concern about regulatory and disclosure risks. ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Disregarded FDA Requirements: SueWallSt
• Negative Sentiment: Robbins LLP notified ADLX stockholders about the class action and invited those who lost money to contact the firm about leading the suit. Robbins LLP Encourages ADLX Stockholders Who Lost Money Investing in Aldeyra Therapeutics, Inc. to Contact the Firm for Information About Leading the Class Action

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.